Details for Patent: 7,399,488

Summary for Patent: 7,399,488

Title:	Abuse-deterrent pharmaceutical compositions of opiods and other drugs
Abstract:	An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, a drug is modified to increase its lipophilicity. In preferred embodiments the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble, but enzymatically degradable by enzymes present in the human gastrointestinal tract. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
Inventor(s):	Jane Hirsh, Alexander M. Kibanov, Timothy M. Swager, Stephen L. Buchwald, Whe Yong Lo, Alison B. Fleming, Roman V. Rariy
Assignee:	Collegium Pharmaceutical Inc
Application Number:	US10/614,866
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,399,488
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound; Dosage form;

US Patent 7,399,488: Claim Scope, Patent Expiration, Abuse-Deterrent Formulations, and Competitive Landscape

US Patent 7,399,488 covers orally administered abuse-deterrent compositions in which a lipophilic abuse-prone drug or derivative is dispersed in hydrophobic microparticles. The central limitation is performance-based: when the dosage form is physically compromised and exposed to water or an aqueous medium, less than the full drug load is released immediately.

The patent is a platform patent rather than a drug-specific patent. Its claims reach oxycodone, hydrocodone, hydromorphone, morphine, oxymorphone, tramadol, methylphenidate, amphetamine and numerous other drugs, but only when combined with the claimed microparticle architecture and abuse-deterrent release behavior.

The patent’s principal commercial significance is historical. It could have created formulation risk for an oral controlled-release product using hydrophobic drug-loaded microparticles, particularly a product designed to resist crushing followed by aqueous extraction. It does not, by itself, cover every abuse-deterrent opioid formulation, every extended-release opioid, or every product containing oxycodone.

What does US Patent 7,399,488 claim?

The independent claims establish two related claim strategies.

Claim	Core subject matter	Principal limitation
1	Oral abuse-deterrent composition with drug-loaded microparticles	Lipophilic drug or derivative dispersed in fats, fatty substances, waxes, wax-like substances or mixtures
2	Oral abuse-deterrent composition with microparticles	Lipophilic derivative dispersed in a slowly water-soluble or water-insoluble carrier
3	Controlled-release version of claim 1 or 2	Adds controlled-release functionality
4	Substantial retardation	Adds a qualitative release limitation
5	Quantitative release limitation	Less than 80% released immediately after compromise
6	Aqueous-medium exposure	Clarifies water or aqueous medium
7	Quantitative aqueous-release limitation	Less than 80% released immediately
8, 24	Drug genus	Lists controlled substances and other abuse-prone drugs
9-15	Drug derivatives	Free bases, free acids, lipophilic salts, metal complexes, cyclodextrin complexes, esters and amides
16-18	Carrier classes	Fats, fatty substances, insoluble proteins, polysaccharides, lipids, phospholipids and cross-linked materials
19-21	Enzymatically degradable coating	Water-insoluble coating degraded by gastrointestinal enzymes
22	Combination therapy	Abuse-prone drug combined with a drug having little or no abuse potential
23	Oxycodone	Expressly narrows the drug to oxycodone
25-26	Manufacturing dispersion	Molten-state dissolution or co-solvent processing
27-28	Specific materials	Fatty-acid counterions and wax or hydrogenated-oil carriers
29	Finished dosage form	Microparticles formulated into a tablet or capsule
30	Narrow drug/material combination	Oxycodone and other named drugs with specified carrier materials

Claims 1 and 2 are the commercial center of gravity. Claims 3 through 30 narrow those claims and provide fallback positions for particular drugs, carriers, coatings, release thresholds and manufacturing methods.

How do claims 1 and 2 differ?

Claim 1 requires a lipophilic drug or lipophilic derivative dispersed in one or more hydrophobic carrier materials. The carrier must be selected from fats, fatty substances, waxes, wax-like substances or mixtures.

Claim 2 is directed specifically to a lipophilic derivative of an abuse-prone drug. It requires a carrier that is slowly soluble or insoluble in water. Claim 2 therefore potentially reaches carriers outside the express fat and wax categories in claim 1, including certain insoluble proteins, polysaccharides, lipids, phospholipids and cross-linked materials identified in dependent claims 16 through 18.

The distinction has practical importance:

• A product using unmodified oxycodone dispersed in carnauba wax is a stronger claim 1 and claim 16-17 candidate.
• A product using a fatty-acid ester or lipophilic salt of oxycodone in an insoluble polymeric matrix may be analyzed first under claim 2.
• A product using a hydrophilic drug salt without a lipophilic derivative faces a stronger non-infringement position, unless the formulation otherwise satisfies the drug and carrier limitations through claim construction or equivalents.

What technical architecture does the patent protect?

The claims require a drug-containing microparticle system, not merely a wax matrix tablet.

The relevant architecture has four functional components:

1. A drug prone to abuse or a lipophilic derivative.
2. A hydrophobic or slowly water-soluble carrier.
3. Microparticles in which the drug is dispersed.
4. Resistance to immediate aqueous extraction after physical damage.

The claimed abuse-deterrent mechanism is different from simple tablet hardness. A tablet can be crushed mechanically, yet the drug remains embedded in hydrophobic particles that resist rapid release when exposed to water.

The claims therefore target a common abuse sequence:

• Crushing or grinding the tablet.
• Exposing the crushed material to water.
• Attempting to extract a concentrated drug solution.
• Administering the extracted material orally or through another route.

The patent focuses on the third step. Physical compromise does not need to leave the microparticles intact in every embodiment, but the compromised composition must retain a release-retarding property when exposed to water or an aqueous medium.

What does “less than 80% released immediately” mean?

Claims 5 and 7 add a quantitative limitation: less than 80% of the total incorporated drug is released immediately after the composition is compromised and exposed to water or an aqueous medium.

The term “immediately” is potentially important in litigation. The claims do not define a single time period in the text supplied. A court would likely examine:

• The specification’s testing protocol.
• The water volume and temperature.
• Particle size after crushing.
• Agitation conditions.
• Extraction duration.
• Assay method.
• Whether “immediate” means an initial burst-release phase or a specified test interval.

Claims 1 and 2 do not expressly require the less-than-80% threshold. A product that fails the quantitative threshold may still fall within claims 1 or 2 if it satisfies the broader functional limitation that release of a portion of the incorporated drug is retarded.

This creates two infringement theories:

Theory	Required showing
Broad independent-claim theory	Some portion of the drug remains release-retarded after physical compromise and aqueous exposure
Quantitative dependent-claim theory	Less than 80% of the drug is released immediately under the applicable test conditions

A generic or branded-product developer would need testing that addresses both theories rather than relying only on an 80% release result.

What formulations are protected by US 7,399,488?

The patent has broad formulation coverage, but its strongest literal coverage is concentrated in the following materials.

Hydrophobic carriers

Claim 28 identifies:

• Stearic acid
• Palmitic acid
• Beeswax
• Carnauba wax
• Hydrogenated oil
• Mixtures of those materials

Claims 16 and 17 separately reach fats and fatty substances. The specification likely provides support for additional waxes and lipid materials, but infringement depends on whether the accused carrier falls within the claim language or an equivalent.

Lipophilic drug derivatives

Claims 9 through 15 cover:

• Free bases
• Free acids
• Salts with lipophilic counterions
• Metal-containing complexes
• Cyclodextrin complexes
• Fatty-acid esters
• Fatty-acid amides

Claim 27 names stearic acid, palmitic acid and myristic acid as counterions. The scope is materially broader than a conventional opioid salt such as oxycodone hydrochloride if that salt is not lipophilic or does not satisfy the derivative limitation.

Coated microparticles

Claims 19 through 21 add a second-level protection strategy. Individual microparticles may carry one or more independent layers, including a water-insoluble layer degraded by gastrointestinal enzymes.

The coating must be more than a conventional enteric coating if the claim requires enzymatic degradation in the gastrointestinal tract. A purely pH-dependent coating may avoid literal infringement of these dependent claims, although the underlying microparticle claims could remain relevant.

Tablets and capsules

Claim 29 confirms that the microparticles may be incorporated into a tablet or capsule. The claim structure indicates that the patent is not limited to free microparticles administered as a powder. It can reach a finished oral dosage form containing the claimed particles.

Which drugs are expressly covered?

The claims list a very broad drug genus, including opioids, benzodiazepines, stimulants, barbiturates, dissociatives and other controlled substances.

The commercially important subset includes:

Drug	Express claim reference	Commercial relevance
Oxycodone	Claim 23 and claim 30	High
Hydrocodone	Claims 8, 24 and 30	High
Hydromorphone	Claims 8, 24 and 30	High
Oxymorphone	Claims 8, 24 and 30	High
Morphine	Claims 8, 24 and 30	High
Tramadol	Claims 8, 24 and 30	Moderate
Methylphenidate	Claims 8, 24 and 30	Moderate
Amphetamine	Claims 8, 24 and 30	Moderate
Fentanyl	Claims 8 and 24	High
Methadone	Claims 8 and 24	Moderate
Buprenorphine	Claim 8	High

The long drug lists do not eliminate the need to prove the formulation limitations. A product containing oxycodone is not within the patent merely because oxycodone appears in claim 23.

What is the patent’s likely infringement scope?

A literal infringement case would generally require proof of each limitation in an asserted claim.

For claim 1, the likely checklist is:

Limitation	Infringement issue
Oral administration	Product label, dosage form and intended route
Abuse-deterrent composition	Claim construction and product design
Therapeutically effective amount	Drug loading and labeled dose
Microparticles	Particle structure, size and manufacturing evidence
Lipophilic drug or derivative	Drug chemistry and partitioning behavior
Fat, fatty, wax or wax-like carrier	Excipient identity and composition
Drug dispersed within carrier	Microscopy, dissolution and manufacturing records
Retarded release after compromise and water exposure	Comparative extraction and release testing

Claim 2 replaces some of the carrier specificity with the requirement for a lipophilic derivative and a slowly soluble or insoluble carrier.

The words “consisting of” may restrict the composition of the microparticles. This can exclude particles containing additional unrecited active structural ingredients, depending on how the term is construed. The tablet or capsule can still contain other excipients under claim 29 because the closed language appears to attach principally to the microparticle composition.

When does US Patent 7,399,488 lose exclusivity?

US Patent 7,399,488 is an early-2000s US utility patent and its ordinary 20-year term runs from the applicable nonprovisional filing date, subject to patent-term adjustment, terminal disclaimers and any patent-term extension. The patent is not a biologic exclusivity right and does not receive a separate statutory exclusivity period merely because it covers an abuse-deterrent formulation.

The patent’s enforceability must be evaluated against the official USPTO Patent Center record, including:

• Earliest effective nonprovisional filing date.
• Patent-term adjustment.
• Continuation or divisional relationships.
• Maintenance-fee status.
• Terminal disclaimers.
• Any certificate of correction or reexamination.
• Any post-grant certificate affecting claim validity.

A patent expiration date cannot be established from the claim text alone. Its current enforceability is separate from whether the patent remains listed in the FDA Orange Book.

What is the Orange Book status of US 7,399,488?

The patent is a platform formulation patent, not a drug-specific patent identified in the supplied claims as covering an approved reference listed drug. Its presence in the Orange Book would therefore depend on a sponsor submitting it for a specific approved product and the FDA accepting the listing.

The Orange Book generally lists patents submitted by an NDA holder that claim:

• The approved drug substance.
• The approved drug product.
• A method of using the approved drug.

A broad abuse-deterrent platform patent may not appear in the Orange Book unless it claims an approved product or an approved method of use. The patent number should not be treated as an Orange Book barrier without a product-specific listing.

For a generic applicant, the relevant regulatory question is not whether the patent exists, but whether it is listed against the reference product and whether the proposed ANDA must include:

• Paragraph I certification.
• Paragraph II certification.
• Paragraph III certification.
• Paragraph IV certification.
• A section viii statement for a method-of-use patent.

Are there Paragraph IV challenges to this patent?

A Paragraph IV certification is available only in the context of an ANDA addressing an Orange Book-listed patent. A generic company does not file a Paragraph IV certification against an unlisted platform patent merely because the patent could be asserted in ordinary infringement litigation.

No product-specific Paragraph IV challenge can be inferred from the claims supplied. The patent’s broad coverage of oxycodone and other controlled substances does not establish that an ANDA applicant challenged it, that litigation was filed, or that a 30-month stay was triggered.

Where a product-specific listing exists, likely Paragraph IV positions would include:

• No microparticles.
• No lipophilic derivative.
• Carrier is not a fat, wax or wax-like material.
• Drug is not dispersed within the carrier.
• No release retardation after crushing and aqueous exposure.
• More than 80% release under the relevant test, for claims 5 and 7.
• Anticipation by prior art.
• Obviousness based on lipid microparticles, controlled-release matrices and abuse-deterrent extraction studies.
• Lack of enablement or written description for the full drug and carrier genera.
• Indefiniteness of “immediately,” “substantially retarded” or “physical integrity.”

How strong is the patent estate?

The patent has broad conceptual reach but mixed practical strength.

Factor	Assessment
Drug coverage	Broad, with explicit opioid and controlled-substance lists
Carrier coverage	Broad at the genus level, strongest for named waxes and fatty materials
Functional limitation	Important but potentially vulnerable to indefiniteness and reproducibility challenges
Quantitative limitation	More objective, but dependent on test conditions
Manufacturing coverage	Narrower and limited to molten-state or co-solvent dispersion
Coating coverage	Narrower, requiring water insolubility and gastrointestinal enzymatic degradation
Product-specific protection	Weak unless tied to an approved formulation or asserted against a matching product
Design-around potential	Significant through non-lipophilic drugs, non-hydrophobic matrices, different particle structures or alternative abuse-deterrence mechanisms

The strongest claims for enforcement are likely claims 1, 2, 5, 7, 16, 17, 23, 28, 29 and 30 when an accused product uses a wax or fatty carrier and an oxycodone or related opioid formulation.

The weakest claims are the very broad drug-list claims when the accused product does not use the claimed particle and release architecture. A list of covered drugs does not substitute for the structural and functional elements.

How does this patent compare with later abuse-deterrent opioid patents?

Later abuse-deterrent opioid patents generally moved toward drug-specific product systems.

Patent strategy	Typical subject matter	Relationship to US 7,399,488
Hydrophobic microparticles	Drug dispersed in fats, waxes or lipids	Direct conceptual overlap
High-hardness tablets	Physical resistance to crushing	Potentially outside the microparticle claims
Sequestered antagonist systems	Opioid combined with antagonist released on tampering	Usually distinct
Ion-exchange resin systems	Drug bound to resin and released under controlled conditions	Usually distinct
Lipidic matrix products	Opioid embedded in fatty excipients	Potential overlap, depending on microparticle structure
Molecular abuse-deterrent derivatives	Covalent or salt derivatives with altered extraction properties	Potential claim 2 overlap
Multi-particulate capsules	Controlled-release beads or pellets	Depends on carrier chemistry and release behavior

Products such as OxyContin, Hysingla ER, Xtampza ER, Arymo ER and RoxyBond have been protected by separate product, formulation and method-of-use patent estates. Their commercial products cannot be assumed to infringe US 7,399,488 solely because they are abuse-deterrent opioids.

The key distinction is whether the marketed product uses drug-loaded hydrophobic microparticles that retain release resistance after crushing and water exposure.

What manufacturing and IP barriers remain?

The patent’s manufacturing claims cover two routes:

• Dissolving the drug or derivative in molten carrier material to create a uniform dispersion.
• Dissolving the drug or derivative in a co-solvent with the carrier before forming the microparticles.

A design-around may use:

• Mechanical encapsulation rather than dissolution.
• Spray drying with a non-lipid matrix.
• Ionic complexation without a lipophilic counterion.
• A nonparticulate monolithic matrix.
• A resin complex.
• A polymeric network with a different release mechanism.
• A coating that is water soluble but physically robust.
• A formulation that uses chemical sequestration instead of hydrophobic extraction resistance.

Manufacturing records would be important in litigation because claims 25 and 26 depend on how the formulation is made, not merely on the final product.

What generic launch risks exist?

For a generic opioid or other controlled substance, the principal risks are separate:

1. Orange Book-listed patents against the reference product.
2. Unlisted patents asserted through ordinary infringement litigation.
3. Regulatory requirements for abuse-deterrent labeling.
4. Controlled-substance quota and diversion controls.
5. Product-specific bioequivalence requirements.
6. Formulation equivalence and abuse-deterrence testing.
7. Manufacturing reproducibility for microparticle size and drug distribution.

If US 7,399,488 is expired or unenforceable, it does not independently block launch. Its technical disclosures may still influence obviousness analyses against later patents, particularly where a later patent claims a wax-based opioid microparticle with similar extraction resistance.

Does the patent create biosimilar risk?

No. The patent concerns small-molecule oral pharmaceutical compositions, not biologics. Biosimilar approval under the Public Health Service Act is not the relevant pathway.

The relevant competitors are:

• ANDA applicants for generic oral dosage forms.
• 505(b)(2) applicants for reformulated abuse-deterrent products.
• Branded controlled-release opioid manufacturers.
• Companies developing non-opioid analgesics or alternative abuse-deterrent delivery systems.

Key Takeaways

• US 7,399,488 is a platform patent for hydrophobic drug-loaded microparticles that resist rapid aqueous extraction after physical compromise.
• Claims 1 and 2 are the principal independent claims.
• The patent expressly reaches oxycodone and numerous other controlled substances, but drug identity alone is insufficient for infringement.
• The most important structural limitations are microparticles, a lipophilic drug or derivative, and a hydrophobic or slowly water-soluble carrier.
• Claims 5 and 7 add a less-than-80% immediate-release threshold.
• Claims 19 through 21 separately address enzyme-degradable, water-insoluble microparticle coatings.
• Claims 25 and 26 cover molten-state and co-solvent manufacturing routes.
• A product-specific Orange Book listing and Paragraph IV challenge cannot be inferred from the patent claims.
• The patent does not cover every abuse-deterrent opioid, every controlled-release formulation or every oxycodone product.
• Current enforceability depends on the official USPTO term, maintenance and prosecution records, not on the claim text alone.
• Later opioid products have generally relied on separate, drug-specific formulation and abuse-deterrence patent estates.

Frequently Asked Questions

Does US 7,399,488 cover ordinary oxycodone tablets?

No. The product would also need to contain the claimed microparticles, lipophilic drug or derivative, carrier materials and post-compromise aqueous release behavior.

Can a polymer matrix avoid US 7,399,488?

Possibly. A polymer matrix that does not contain the claimed microparticle structure or specified carrier may avoid literal infringement, although the factual formulation and any equivalents analysis remain decisive.

Is the 80% release threshold required for all claims?

No. The threshold appears in dependent claims 5 and 7. Claims 1 and 2 use broader release-retardation language.

Does an abuse-deterrent label create patent protection?

No. FDA abuse-deterrent labeling and patent rights are separate. Regulatory recognition does not establish infringement or patent validity.

Can a 505(b)(2) applicant rely on patent expiration?

A 505(b)(2) applicant may rely on expiration of a relevant patent, but it must separately address Orange Book certifications, remaining patents, regulatory exclusivity and any litigation risk associated with the proposed formulation.

References

1. United States Patent and Trademark Office. (2008). US Patent No. 7,399,488, Abuse-deterrent pharmaceutical compositions. U.S. Department of Commerce.

2. United States Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.

3. United States Food and Drug Administration. (2015). Guidance for industry: Abuse-deterrent opioids: Evaluation and labeling. U.S. Department of Health and Human Services.

4. United States Code, 35 U.S.C. §§ 154, 271, 282. (2024). Patent term, infringement and validity provisions.

5. United States Code, 21 U.S.C. § 355. (2024). New drug applications, abbreviated applications and patent certifications.

Drugs Protected by US Patent 7,399,488

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,399,488

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003247876
Canada	2491572
Canada	2569958
Canada	2916869